We optimize biopharmaceutical R&D productivity, commercial value, and patient outcomes through our scalable end-to-end platform integrating biosimulation, regulatory science, and market access solutions.
Our customers include more than 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries. Since 2014, customers who use Certara’s biosimulation software and technology-enabled services have received over 90% of all new drug and biologic approvals by the FDA.
Certara Releases New Versions of Its Preeminent Quantitative Systems Pharmacology (QSP) Simulators for Expediting Development of Biologics and Immuno-oncology Therapies
May 13, 2021
Expanded capabilities in company’s Immunogenicity and Immuno-oncology QSP Simulators broaden applicability for addressing safety and efficacy challenges PRINCETON, N.J. , May 13, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), the global leader in biosimulation, today announced the launch of
Certara Reports First Quarter 2021 Financial Results and Updates Full Year 2021 Guidance
May 06, 2021
PRINCETON, N.J. , May 06, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2021. Highlights: Revenue was $66.7 million , representing growth of 16% over the first quarter of 2020.
Certara Launches Secondary Intelligence™ Software to Predict Risk of Unwanted Side Effects of Drug Candidates Earlier
May 04, 2021
First-of-its-kind software predicts likelihood of off-target safety issues that could impede clinical progress PRINCETON, N.J. , May 04, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), the global leader in biosimulation, today announced the launch of its Secondary Intelligence™ software, the